Enable Injections, a drug delivery combination product company developing advanced wearable devices for subcutaneous delivery of high-volume therapeutics, has entered into development agreements with Apellis Pharmaceuticals, and most recently, UCB. The company currently has partnerships with five companies to deliver products that shift treatment to the home with self-administration of new large-volume drugs.   The rapidly growing pipeline of large-volume therapeutics, with thousands in develo...